(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV

(PQ3) 解决艾滋病毒感染者的癌症治疗差异

• 批准号: 10617295
• 负责人: Elizabeth Chiao
• 金额: $ 80.73万
• 依托单位: KAISER FOUNDATION RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-15 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10617295
• 关键词: Accounting; Acquired Immunodeficiency Syndrome; Address; Adverse event; Aftercare; Age; Antitumor Response; Anus; CD4 Lymphocyte Count; Cancer Survivor; Cardiac; Caring; Cause of Death; Chronic; Clinical Trials; Data; Diagnosis; Disease; Disparity; Dose; Electronic Health Record; Etiology; Event; Exclusion; General Population; Goals; HIV; HIV Infections; HIV diagnosis; Head and Neck Cancer; Health; Health system; Hospitalization; Immune system; Immunologics; Immunosuppression; Institution; Integrated Health Care Systems; Intervention; Kidney; Knowledge; Late Effects; Life Expectancy; Lung; Lymphocyte; Lymphopenia; Malignant Neoplasms; Malignant neoplasm of anus; Malignant neoplasm of lung; Malignant neoplasm of prostate; Medical Oncologist; Metabolic; Neck Cancer; Non-Small-Cell Lung Carcinoma; Outcome; Patients; Persons; Process; Publishing; Radiation Oncologist; Radiation therapy; Recovery; Recurrence; Recurrent Malignant Neoplasm; Regimen; Risk; Risk Factors; Safety; Sampling; Second Primary Cancers; Serious Adverse Event; Single-Payer System; Site; Toxic effect; United States; United States Department of Veterans Affairs; antiretroviral therapy; cancer care; cancer initiation; cancer recurrence; cancer risk; cancer survival; cancer therapy; care delivery; care outcomes; care providers; chemotherapy; common treatment; comorbidity; data resource; demographics; dosage; high risk; improved; improved outcome; mortality; mortality risk; neutrophil; novel; observational cohort study; provider factors; study population; survival disparity; survivorship; therapy outcome; treatment disparity; treatment guidelines

PROJECT SUMMARY/ABSTRACT The introduction of combination antiretroviral therapy (ART) has led to a dramatic decline in AIDS-associated mortality. However, as persons with HIV (PWH) age, mortality from non-AIDS-defining cancer (NADC) continues to increase and is now the leading cause of death for PWH. Recent studies have demonstrated persistent disparities in both initiation of cancer therapy and survival among PWH and cancer compared with the general population. This may be due in part to medical and radiation oncologists' concerns regarding the safety and efficacy of cancer treatment for PWH. Alternatively, it is possible that chemotherapy with radiation therapy (CRT) and radiation therapy (RT) alone may be less effective in PWH or associated with greater toxicity. It is well established that positive cancer outcomes are dependent on successful navigation of all steps in the cancer care delivery process, including: timely treatment initiation, treatment completion, and treatment safety, defined by avoidance of serious adverse events (SAEs). It is also critical to evaluate the ongoing health needs of cancer survivors with HIV, including the risk of long-term chronic health conditions (i.e., late adverse effects) after cancer treatment. Prior studies have evaluated cancer treatment initiation rates for certain cancers, however, there have been no published studies that have comprehensively evaluated differences in outcomes at other key steps in the cancer care delivery process for PWH compared with people without HIV (HIV-), nor have there been studies that have evaluated patient- and provider-factors that might contribute to disparities at each step. We propose the following Specific Aims which will address these critical knowledge gaps for the four most common NADCs in PWH treated with CRT/RT (anal, head and neck, lung, or prostate cancer): Aim 1: To evaluate differences in the timing of cancer treatment initiation between PWH and matched HIV- with cancer, and risk factors for delayed treatment in PWH. Aim 2: To evaluate disparities in short-term SAEs and cancer treatment completions between PWH and matched HIV- patients who initiated CRT/RT. Aim 3: To evaluate the long-term risk of mortality and cancer recurrence comparing PWH with cancer and matched HIV- patients. Aim 4: To compare risk of chronic health conditions among PWH with cancer, with (a) HIV- with cancer and (b) PWH without cancer. In addition to evaluating differences in outcomes between PWH and HIV- patients with cancer, study aims will also evaluate the impacts of key potential risk factors, including: ART regimens, immunosuppression, and treatment dosage and completion, which may be associated with CRT/RT outcomes. This observational cohort study will identify >3,000 PWH diagnosed with cancer, 1:1 matched HIV- persons with the same cancers, and 4:1 matched PWH without cancer who have received care from the Veteran's Administration or Kaiser Permanente, the two largest single-payer integrated healthcare systems in the United States. Study findings will provide data to provide targets for cancer care delivery and treatment interventions, and inform HIV-specific cancer treatment guidelines to improve cancer survival among PWH.

项目总结/文摘

项目成果

Survival outcomes in veterans with hepatocellular carcinoma, with and without HIV infection.

患有肝细胞癌的退伍军人（无论是否感染艾滋病毒）的生存结果。

• DOI: 10.1097/qad.0000000000003568
• 发表时间: 2023
• 期刊: AIDS (London, England)
• 作者: Sada,YvonneH;daCostaJr,WilsonL;Kramer,JenniferR;Chiao,ElizabethY;Zafeiropoulou,Efthalia;Dong,Yongquan;Chen,Liang;Dang,BichN
• 通讯作者: Dang,BichN

Incidence Trends of Kaposi Sarcoma Among Young Non-Hispanic Black Men by US Regions, 2001-2018.

• DOI: 10.1093/jncics/pkac078
• 发表时间: 2022-11-01
• 期刊: JNCI cancer spectrum
• 影响因子: 4.4